LA-MeO
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LA-MeO, also known as lysergic acid ethyl-2-methoxyethylamide or as N-ethyl-N-(2-methoxyethyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the O-methyl ether derivative of the LSD metabolite lysergic acid ethyl-2-hydroxyethylamide (LEO).[1][2]
- None
| Clinical data | |
|---|---|
| Other names | LSD-MeO; Lysergic acid ethyl-2-methoxyethylamide; N-Ethyl-N-(2-methoxyethyl)lysergamide; LEO O-methyl ether; N-Ethyl-N-(2-methoxyethyl)-6-methyl-9,10-didehydroergoline-8β-carboxamide |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C21H27N3O2 |
| Molar mass | 353.466 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug shows high affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 4.0 nM, 7.1 nM, and 7.8 nM, respectively).[1][2] It acts as a potent partial agonist of the serotonin 5-HT2A receptor similarly to LSD, with an EC50 of 30.3 nM and an Emax of 29.6% (relative to 8.4 nM and 22.4% in the case of LSD, respectively).[1][2]
LA-MeO was first described in the scientific literature by Jason C. Parrish of the lab of David E. Nichols at Purdue University by 2007.[1][2]